Ballicules.com

Progesterone

endogenous

What it isProgesterone-receptor agonist; endometrial protection with estrogen and luteal support.

Why this oneIt is the endogenous hormone rather than a synthetic progestin, with less adverse lipid effect than medroxyprogesterone.

What limits itSedation favors bedtime use. Oral absorption is variable, and the capsule's peanut oil matters in severe allergy.

FDA-approved for

FDA label

BOXED WARNING Estrogen plus progestin therapy: increased risk of cardiovascular disorders, breast cancer, and probable dementia; do not use for prevention of cardiovascular disease or dementia.
FDA dosingPopulationStartTargetMax
Prevention of endometrial hyperplasia (postmenopausal, on estrogen)Adult200 mg QHS x12 sequential days per 28-day cycle
Secondary amenorrheaAdult400 mg QHS x10 days

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Should not be used during pregnancy (contraindicated); Category B

Lactation Undefined

NO BOXED WARNINGS

Principal riskSedation; it is a peanut oil formulation

Cost, est. cash$20–$1,500/dose or month

Generic entry2001

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryX

Defining liabilityVenous thromboembolism and hormone-related adverse effects; estrogen also lowers lamotrigine exposure.

Active metabolites

Mechanism of action: Progesterone ballicule

Progesterone ballicule: receptor binding, kinetics and half-life diagram

Open Progesterone in the interactive console ↗